8-K Announcements
6Material company update
Jun 10, 2026·SEC
Material company update
Jun 4, 2026·SEC
Material company update
Mar 17, 2026·SEC
Aethlon Medical, Inc.(AEMD)Earnings, Financials & Key Ratios
AEMD•NASDAQ
Price updated Jun 19, 2026
AboutAethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$7M+22.6%
- Net Income-$7M+46.6%
- EPS (Diluted)-10.61+87.6%
- ROE-142.89%+41.9%
AEMD Key Insights
Aethlon Medical, Inc. (AEMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AEMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AEMD Price & Volume
Aethlon Medical, Inc. (AEMD) stock price & volume — 10-year historical chart
Loading chart...
AEMD Growth Metrics
Aethlon Medical, Inc. (AEMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM46.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.84%
Return on Capital
10 Years-138.58%
5 Years-111.87%
3 Years-137.01%
Last Year-140.99%
AEMD Recent Earnings
Aethlon Medical, Inc. (AEMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q3 2026Latest
Jun 10, 2026Metric
Actual
Est
EPS
$4.08+288.4%
$2.17
Rev
—
—
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.45-21.9%
$2.01
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$3.74-120.0%
$1.70
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$8.50-25.0%
$6.80
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 10, 2026 | $4.08vs $2.17+288.4% | — |
| Q1 2026 | Feb 12, 2026 | $2.45vs $2.01-21.9% | — |
| Q4 2025 | Nov 12, 2025 | $3.74vs $1.70-120.0% | — |
| Q3 2025 | Aug 13, 2025 | $8.50vs $6.80-25.0% | — |
Based on last 12 quarters of dataView full earnings history →
AEMD Peer Comparison
Aethlon Medical, Inc. (AEMD) competitors in Renal, dialysis, and blood purification — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XTLB | 279.46K | 2.54 | -0.26 | -227.72% | -25.53% | 0.03 | ||
 EKSO | 56.89M | 23.45 | -4.78 | -28.6% | -135.66% | -177.4% | 0.29 | |
 PRTH | 590.49M | 7.17 | 10.54 | 8.33% | 5.85% | |||
 TELA | 36.85M | 0.82 | -0.99 | 15.84% | -49.3% | -13.44% | 8.82 | |
 BAX | 10.27B | 19.89 | -11.37 | 5.72% | -9.7% | -16.5% | 1.64 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare AEMD vs Peers
Aethlon Medical, Inc. (AEMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AEMD Income Statement
Aethlon Medical, Inc. (AEMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 149.63K | 229.63K | 650.19K | 659.1K | 294.17K | 574.25K | 0 | 0 | 0 |
Revenue Growth % | -61.84% | 53.47% | 183.15% | 1.37% | -55.37% | 95.21% | -100% | - | - |
Cost of Goods Sold | 2.63B | 3.08B | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | 1761027.23% | 1342674.36% | - | - | - | - | - | - | - |
Gross Profit | -2.49B▲ 0% | -2.85B▼ 14.8% | 650.19K▲ 100.0% | 659.1K▲ 1.4% | 294.17K▼ 55.4% | 574.25K▲ 95.2% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | -1661027.23% | -1242674.36% | 100% | 100% | 100% | 100% | - | - | - |
Gross Profit Growth % | 19.5% | -14.81% | 100.02% | 1.37% | -55.37% | 95.21% | -100% | - | - |
Operating Expenses | 4.98M | 6.23M | 6.58M | 8.55M | 10.72M | 12.47M | 12.64M | 9.34M | 7.29M |
OpEx % of Revenue | 3328.99% | 2712.68% | 1012.04% | 1297.31% | 3642.53% | 2172.05% | - | - | - |
Selling, General & Admin | 4.98M | 6.23M | 6.58M | 8.55M | 10.72M | 12.47M | 12.64M | 9.34M | 2.7M |
SG&A % of Revenue | 3328.82% | 2712.68% | 1012.04% | 1297.31% | 3642.53% | 2172.05% | - | - | - |
Research & Development | 586K | 896K | 927K | 2.07M | 2.34M | 2.75M | 2.52M | 2.21M | 0 |
R&D % of Revenue | 391.65% | 390.2% | 142.57% | 314.37% | 795.81% | 478.02% | - | - | - |
Other Operating Expenses | -586K | -896K | -927K | -2.07M | -2.34M | -2.75M | -2.52M | -2.21M | 4.6M |
Operating Income | -4.83M▲ 0% | -6M▼ 24.2% | -5.93M▲ 1.2% | -7.89M▼ 33.1% | -10.42M▼ 32.1% | -11.9M▼ 14.2% | -12.64M▼ 6.2% | -9.34M▲ 26.1% | -7.29M▲ 21.9% |
Operating Margin % | -3228.74% | -2612.52% | -912.04% | -1197.31% | -3542.53% | -2072.05% | - | - | - |
Operating Income Growth % | 20.78% | -24.18% | 1.15% | -33.08% | -32.05% | -14.18% | -6.2% | 26.08% | 21.92% |
EBITDA | -4.8M | -5.97M | -5.9M | -7.85M | -10.3M | -11.66M | -12.28M | -9M | -6.97M |
EBITDA Margin % | -3204.91% | -2599.15% | -907.99% | -1191.25% | -3500.48% | -2030.1% | - | - | - |
EBITDA Growth % | 20.94% | -24.46% | 1.08% | -33% | -31.15% | -13.21% | -5.32% | 26.68% | 22.57% |
D&A (Non-Cash Add-back) | 35.66K | 30.7K | 26.37K | 39.94K | 123.69K | 240.89K | 359.06K | 339.56K | 323.65K |
EBIT | -5.34M | -6M | -5.93M | -7.89M | -10.42M | -12.03M | -12.21M | -13.38M | -7.14M |
Net Interest Income | -362K | -220K | -54.23K | -1.58K | 0 | 10.97K | 428.39K | 288.01K | 142.16K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 10.97K | 428.39K | 298.12K | 156.53K |
Interest Expense | 361.6K | 220.49K | 54.23K | 1.58K | 0 | 0 | 0 | 10.11K | 14.37K |
Other Income/Expense | -869K | -220K | -450.05K | 0 | 0 | -131.15K | 428.39K | -4.05M | 142.16K |
Pretax Income | -5.7M▲ 0% | -6.22M▼ 9.1% | -6.38M▼ 2.6% | -7.89M▼ 23.7% | -10.42M▼ 32.1% | -12.03M▼ 15.4% | -12.21M▼ 1.5% | -13.39M▼ 9.7% | -7.15M▲ 46.6% |
Pretax Margin % | -3809.52% | -2708.76% | -981.26% | -1197.31% | -3542.53% | -2094.89% | - | - | - |
Income Tax | 0 | -24.79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0.4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -5.68M▲ 0% | -6.2M▼ 9.1% | -6.37M▼ 2.9% | -7.89M▼ 23.7% | -10.42M▼ 32.1% | -12.03M▼ 15.5% | -12.21M▼ 1.5% | -13.39M▼ 9.7% | -7.15M▲ 46.6% |
Net Margin % | -3796.16% | -2697.88% | -980.33% | -1196.58% | -3540.9% | -2094.89% | - | - | - |
Net Income Growth % | 21.94% | -9.07% | -2.89% | -23.73% | -32.07% | -15.49% | -1.48% | -9.66% | 46.58% |
Net Income (Continuing) | -5.7M | -6.22M | -6.38M | -7.89M | -10.42M | -12.03M | -12.21M | -13.39M | -7.15M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -101.25K | -126.03K | -132.12K | -136.91K | -141.71K | 0 | 0 | 0 | 0 |
EPS (Diluted) | -691.70▲ 0% | -512.70▲ 25.9% | -186.70▲ 63.6% | -65.20▲ 65.1% | -70.60▼ 8.3% | -58.60▲ 17.0% | -48.60▲ 17.1% | -85.80▼ 76.5% | -10.61▲ 87.6% |
EPS Growth % | 50.94% | 25.88% | 63.58% | 65.08% | -8.28% | 17% | 17.06% | -76.54% | 87.63% |
EPS (Basic) | -691.70 | -513.00 | -186.70 | -65.20 | -70.60 | -58.60 | -48.60 | -85.80 | -10.61 |
Diluted Shares Outstanding | 8.21K | 12.08K | 34.15K | 120.9K | 147.6K | 205.4K | 251.3K | 156.08K | 673.95K |
Basic Shares Outstanding | 8.21K | 12.08K | 34.15K | 120.9K | 147.6K | 205.4K | 251.3K | 156.08K | 673.95K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
AEMD Balance Sheet
Aethlon Medical, Inc. (AEMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.23M | 4.04M | 10.04M | 10.35M | 18.16M | 15.09M | 6.23M | 5.95M | 5.57M |
Cash & Short-Term Investments | 6.97M | 3.83M | 9.6M | 9.86M | 17.07M | 14.53M | 5.44M | 5.5M | 5.03M |
Cash Only | 6.97M | 3.83M | 9.6M | 9.86M | 17.07M | 14.53M | 5.44M | 5.5M | 5.03M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 74.81K | 0 | 206.73K | 149.08K | 127.97K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 182.5 | - | 116.05 | 82.56 | 158.78 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 557.62K | 783.81K | 448.54K | 543.08K |
Total Non-Current Assets | 121.65K | 84.85K | 346.57K | 317.18K | 1.26M | 2.42M | 2.02M | 1.41M | 763.57K |
Property, Plant & Equipment | 27.55K | 6.02K | 276.91K | 201.34K | 1.14M | 2.3M | 1.9M | 1.28M | 664.64K |
Fixed Asset Turnover | 5.43x | 38.14x | 2.35x | 3.27x | 0.26x | 0.25x | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 75.83K | 66.67K | 57.5K | 56.95K | 2.2K | 1.65K | 1.1K | 550 | 0 |
Long-Term Investments | 0 | 0 | 0 | 46.73K | 87.51K | 87.51K | 87.51K | 97.81K | 0 |
Other Non-Current Assets | 18.27K | 12.16K | 12.16K | 58.88K | 120.81K | 120.81K | 33.3K | 33.3K | 98.93K |
Total Assets | 7.35M▲ 0% | 4.12M▼ 43.9% | 10.39M▲ 151.9% | 10.67M▲ 2.7% | 19.42M▲ 82.0% | 17.51M▼ 9.8% | 8.25M▼ 52.9% | 7.36M▼ 10.8% | 6.33M▼ 13.9% |
Asset Turnover | 0.02x | 0.06x | 0.06x | 0.06x | 0.02x | 0.03x | - | - | - |
Asset Growth % | 325.86% | -43.92% | 151.95% | 2.71% | 82% | -9.83% | -52.9% | -10.75% | -13.95% |
Total Current Liabilities | 477.96K | 1.82M | 1.07M | 1.38M | 1.82M | 1.51M | 1.83M | 1.9M | 1.45M |
Accounts Payable | 124.45K | 131.93K | 285.04K | 337.68K | 499.96K | 432.89K | 777.86K | 534.52K | 384.55K |
Days Payables Outstanding | 0.02 | 0.02 | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 962.3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 100K | 114.85K | 344.55K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 374.46K | 0 | 595.89K | 0 | 0 | 0 | 178.21K | 68.25K |
Current Ratio | 15.13x | 2.21x | 9.40x | 7.53x | 9.95x | 10.03x | 3.40x | 3.13x | 3.85x |
Quick Ratio | 15.13x | 2.21x | 9.40x | 7.53x | 9.95x | 10.03x | 3.40x | 3.13x | 3.85x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 841.15K | 0 | 42.54K | 0 | 602.5K | 939.64K | 649.75K | 336.72K | 0 |
Long-Term Debt | 841.15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 42.54K | 0 | 602.5K | 939.64K | 649.75K | 336.72K | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.32M | 1.82M | 1.11M | 1.38M | 2.43M | 2.44M | 2.48M | 2.24M | 1.45M |
Total Debt | 841.15K | 962.3K | 141.1K | 42.54K | 729.41K | 1.21M | 940.32K | 649.75K | 336.72K |
Net Debt | -6.13M | -2.87M | -9.46M | -9.82M | -16.34M | -13.32M | -4.5M | -4.85M | -4.69M |
Debt / Equity | 0.14x | 0.42x | 0.02x | 0.00x | 0.04x | 0.08x | 0.16x | 0.13x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -14.76x | -27.21x | -109.34x | -4994.62x | - | - | - | -1323.37x | -496.60x |
Total Equity | 6.03M▲ 0% | 2.3M▼ 61.9% | 9.28M▲ 303.5% | 9.29M▲ 0.2% | 16.99M▲ 82.8% | 15.06M▼ 11.3% | 5.77M▼ 61.7% | 5.12M▼ 11.1% | 4.89M▼ 4.6% |
Equity Growth % | 913.21% | -61.89% | 303.53% | 0.18% | 82.83% | -11.34% | -61.72% | -11.15% | -4.63% |
Book Value per Share | 734.69 | 190.27 | 271.68 | 76.87 | 115.12 | 73.34 | 22.95 | 32.83 | 7.25 |
Total Shareholders' Equity | 6.13M | 2.43M | 9.41M | 9.43M | 17.13M | 15.06M | 5.77M | 5.12M | 4.89M |
Common Stock | 17.74K | 1.27K | 9.37K | 12.15K | 15.42K | 22.99K | 2.63K | 2.59K | 1.57K |
Retained Earnings | -99.46M | -105.65M | -112.03M | -119.91M | -130.33M | -142.36M | -154.57M | -167.95M | -175.11M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | -6.14K | -6.94K | -17.13K | -32.7K |
Minority Interest | -101.25K | -126.03K | -132.12K | -136.91K | -141.71K | 0 | 0 | 0 | 0 |
AEMD Cash Flow Statement
Aethlon Medical, Inc. (AEMD) cash flow — operating, investing & free cash flow history
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.91M | -4.29M | -5.2M | -6.76M | -9.77M | -10.51M | -10.13M | -7.65M | -7T |
Operating CF Margin % | -2613.65% | -1869.76% | -799.4% | -1026.38% | -3320.3% | -1829.38% | - | - | - |
Operating CF Growth % | -11.55% | -9.79% | -21.06% | -30.15% | -44.38% | -7.56% | 3.57% | 24.52% | -91535610.01% |
Net Income | -5.7M | -6.22M | -6.38M | -7.89M | -10.42M | -12.03M | -12.21M | -13.39M | -7.15T |
Depreciation & Amortization | 35.66K | 30.7K | 26.37K | 39.94K | 123.69K | 240.89K | 359.06K | 339.56K | 323.65B |
Stock-Based Compensation | 1.26M | 1.32M | 844K | 779.42K | 750.62K | 1.05M | 1.22M | 415.23K | 278.55B |
Deferred Taxes | 507.12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 279.26K | 140.5K | 427.07K | -2.49K | 30.53K | 166.53K | 21.28K | 4.89M | -449.12B |
Working Capital Changes | -293.66K | 435.88K | -115K | 309.69K | -251.11K | 65.34K | 478.66K | 93.69K | -743K |
Change in Receivables | -74.81K | 74.81K | -206.73K | 57.65K | 21.12K | 127.97K | 0 | 0 | 0 |
Change in Inventory | -6.87M | -74.81K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -104.15K | 390.34K | -16.77K | 341.86K | 97.54K | -174.73K | 156.68K | -53.36K | -383K |
Cash from Investing | -24.82K | 0 | -151.66K | -59.88K | -349.19K | -943.11K | -250.87K | 0 | -3.7B |
Capital Expenditures | -24.82K | 0 | -151.66K | -59.88K | -349.19K | -943.11K | -250.87K | 0 | -3.7B |
CapEx % of Revenue | 16.59% | - | 23.33% | 9.09% | 118.71% | 164.23% | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 9.35M | 1.15M | 11.13M | 7.13M | 17.37M | 8.91M | 1.29M | 7.73M | 6.52T |
Debt Issued (Net) | 0 | 0 | -992.59K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 9.35M | 1.15M | 12.16M | 7.26M | 17.46M | 8.93M | 1.32M | 3.54M | 6.66M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -278.63K | -193.87K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -40.94K | -132.53K | -88.12K | -12.49K | -34.78K | 4.19M | 6.52T |
Net Change in Cash | 5.41M▲ 0% | -3.15M▼ 158.1% | 5.78M▲ 283.6% | 303.52K▼ 94.7% | 7.25M▲ 2289.2% | -2.54M▼ 135.0% | -9.09M▼ 258.0% | 69.59K▲ 100.8% | -473.69B▼ 680684106.3% |
Free Cash Flow | -3.94M▲ 0% | -4.29M▼ 9.1% | -5.35M▼ 24.6% | -6.82M▼ 27.6% | -10.12M▼ 48.2% | -11.45M▼ 13.2% | -10.38M▲ 9.3% | -7.65M▲ 26.3% | -7T▼ 91584056.6% |
FCF Margin % | -2630.24% | -1869.76% | -822.73% | -1035.47% | -3439.01% | -1993.62% | - | - | - |
FCF Growth % | -11.73% | -9.09% | -24.59% | -27.58% | -48.23% | -13.17% | 9.33% | 26.35% | -91584056.6% |
FCF per Share | -479.27 | -355.33 | -156.65 | -56.45 | -68.54 | -55.74 | -41.31 | -48.98 | -999999.00 |
FCF Conversion (FCF/Net Income) | 0.69x | 0.69x | 0.82x | 0.86x | 0.94x | 0.87x | 0.83x | 0.57x | 978595.03x |
Interest Paid | 0 | 0 | 83.33K | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEMD Key Ratios
Aethlon Medical, Inc. (AEMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -693.69% | -171.39% | -148.71% | -110.12% | -84.94% | -79.25% | -75.06% | -117.21% | -245.88% | -142.89% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -12703.34% | -747.19% | -630.78% | -911.83% | -2334.95% |
Gross Margin | -787423.26% | -1661027.23% | -1242674.36% | 100% | 100% | 100% | 100% | - | - | - |
Net Margin | -1855.78% | -3796.16% | -2697.88% | -980.33% | -1196.58% | -3540.9% | -2094.89% | - | - | - |
Debt / Equity | 0.87x | 0.14x | 0.42x | 0.02x | 0.00x | 0.04x | 0.08x | 0.16x | 0.13x | 0.07x |
Interest Coverage | -23.01x | -14.76x | -27.21x | -109.34x | -4994.62x | - | - | - | -1323.37x | -496.60x |
FCF Conversion | 0.48x | 0.69x | 0.69x | 0.82x | 0.86x | 0.94x | 0.87x | 0.83x | 0.57x | 978595.03x |
Revenue Growth | -55.78% | -61.84% | 53.47% | 183.15% | 1.37% | -55.37% | 95.21% | -100% | - | - |
Related:AEMD Dividend History·AEMD Revenue History·AEMD Price History·AEMD P/E History·AEMD Financial Ratios·AEMD Institutional Holders
AEMD SEC Filings & Documents
Aethlon Medical, Inc. (AEMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
AEMD Frequently Asked Questions
Aethlon Medical, Inc. (AEMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aethlon Medical, Inc. (AEMD) grew revenue by 0.0% over the past year. Growth has been modest.
Aethlon Medical, Inc. (AEMD) reported a net loss of $7.2M for fiscal year 2026.
Dividend & Returns
Aethlon Medical, Inc. (AEMD) has a return on equity (ROE) of -142.9%. Negative ROE indicates the company is unprofitable.
Aethlon Medical, Inc. (AEMD) had negative free cash flow of $7.00T in fiscal year 2026, likely due to heavy capital investments.